Tumor mutational burden (TMB)
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
... tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) ...on TMB should be clarified. We ...
5
<p>Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China</p>
... Tumor mutational burden (TMB) has demonstrated itself as a new estimated biomarker in ...with TMB- high had prolonged PFS after they received PD-1/PD-L1 blockade, compared with patients ...
8
Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’
... Thymoma; TMB: Tumor mutational burden; UCEC: Uterine corpus endometrial carcinoma; UCS: Uterine carcinosarcoma; UVM: Uveal melanoma; WES: Whole exome ...
7
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
... highest mutational loads across cancer types, likely owing to tobacco-induced mutagen- esis, which is characterized by a high transversion/transi- tion ratio and increased genomic instability ...quantify ...
9
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
... the tumor mutational burden (TMB), defined as the total number of mutations per coding area of a tumor ...Each tumor mutation within a cancer cell has the potential to give rise ...
11
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
... Circulating tumor DNA; DLBC: Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; FDA: Food and Drug Administration; GBM: Glioblastoma; GEP: Gene expression profile; HLA: Human Leukocyte ...
13
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
... high TMB, as expected (Additional file 3: Table ...high TMB may represent an opportunity to expand the list of indications that respond favorably to immune check- point ...overall TMB, we also found ...
14
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
... higher TMB predicted favor- able outcome to PD-1/PD-L1 blockade Immunotherapy in several cancers [20, 22, ...Low/moderate TMB group and High TMB group. As shown in Table 4, TMB status solely ...
14
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
... The clinical trials for mUC and mRCC mentioned above highlight the numerous challenges facing PD-L1 as a biomarker. First, there is no standardized format to assess PD-L1 immunohistochemically. Several pharma- ceutical ...
10
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
... by tumor cells as well as detection of intratumoral microsatel- lite instability (MSI-H) were approved as inclusion criteria for anti-PD1 treatment of cancer ...nonsynonymous tumor mutational ...
8
Extraskeletal myxoid chondrosarcoma with massive pulmonary metastases
... tumor size was 14.8 cm in greatest dimension, the clos- est margin was less than 0.5 mm from the tumor. Next generation sequencing (NGS) was performed using a commercially available platform; it showed the ...
6
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
... against tumor cells, have shown immense promise in the treatment of various ...Currently, tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are the primary ...
18
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
... by tumor biomarker sta- tus makes it important to fully understand how dMMR affects the immune ...increased tumor mutational burden promotes neoantigen expression and T-cell expansion, which ...
7
Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014†
... all TMB practitioner authored case reports in the scientific lit- erature prior to ...larger TMB case report re- view project, we focus specifically on how the audit was developed and completed, and the ...
12
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
... Because tumor tissues were tested without a paired normal from individual patients, additional informatics steps were taken to identify common single nucleotide polymorphisms (SNPs): any SNP present at greater ...
14
Genomic case report of a low grade bladder tumor metastasis to lung
... metastatic tumor and has a VAF of 1% (of 160 reads) in the primary bladder ...mary tumor probably developed this particular MTOR mutation and this clonal population likely migrated and was able to seed in ...
7
Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types
... Immunotherapies, such as the suppression of immune checkpoints (αPD-1, αPD-L1), have revolutionized the treatment of human cancers [39–45]. The immune checkpoints (i.e. PD-1, PD-L1 and CTLA-4) and other immune-related ...
13
Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014†
... Manuscript Heading: Discussion No clear manuscript heading identified N/A - No corresponding section included 35. Discussion: Check the box if the following Clear acknowledgment of inher[r] ...
10
Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report
... Multiple primary cancer (MPC) is defined as the simultan- eous (synchronous) or successive (metachronous) develop- ment of independent primary malignant tumors in one or multiple organs in the same individual. The ...
7
Mutational load in carotid body tumor
... against tumor-expressing ...in tumor cells, and the potential of neoantigen formation is correlated with mutational load (ML) ...in tumor cells, and tumor-infiltrating lymphocytes ...
12